JANX
Janux Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow -1.2% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | 0 | 35.14M | $539.55M | +6 | −6 |
| Q1 2026 | 80 | +4 | 31.30M | $434.70M | +12 | −8 |
| Q4 2025 | 75 | +1 | 36.09M | $498.13M | +1 | — |
| Q3 2025 | 15 | 0 | 27.21M | $664.97M | — | — |
| Q2 2025 | 12 | 0 | 25.28M | $583.88M | +1 | −1 |
| Q1 2025 | 9 | -2 | 8.77M | $236.76M | — | −2 |
| Q4 2024 | 11 | 0 | 8.88M | $475.25M | +1 | −1 |
| Q3 2024 | 10 | +1 | 4.53M | $205.89M | +1 | — |
| Q2 2024 | 9 | — | 5.15M | $215.67M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.65M | +19.4% | $98.67M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.39M | +25.5% | $37.61M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 1.37M | +8.2% | $37.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 780.91K | +9.2% | $21.09M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 706.66K | -48.1% | $19.08M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 393.48K | -26.5% | $10.62M | 0.0% | ▼ Trim | 4 | SEC ↗ ×6 |
| 7 | Point72 Asset Management ✦ | 376.66K | -39.4% | $10.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Millennium Management ✦ | 82.27K | -29.1% | $2.22M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 9.72K | +71.7% | $262,359 | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $3.21M | was 0.0% |
| Marshall Wace | $1.20M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 59.36M shares, $809.28M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.